Immuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of “Buy” from Brokerages

Immuneering Co. (NASDAQ:IMRXGet Rating) has been assigned a consensus rating of “Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $34.00.

A number of research firms have weighed in on IMRX. Guggenheim decreased their price objective on shares of Immuneering from $42.00 to $30.00 in a research report on Monday, January 3rd. Zacks Investment Research cut shares of Immuneering from a “buy” rating to a “hold” rating in a research report on Monday, March 14th. Oppenheimer began coverage on shares of Immuneering in a research report on Thursday, March 31st. They issued an “outperform” rating and a $25.00 price objective for the company. Piper Sandler assumed coverage on shares of Immuneering in a research report on Friday, January 7th. They issued an “overweight” rating and a $41.00 price objective for the company. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price target on shares of Immuneering in a research report on Thursday, December 30th.

In other Immuneering news, Director Ann E. Berman bought 6,000 shares of the business’s stock in a transaction on Tuesday, March 15th. The shares were purchased at an average price of $6.40 per share, with a total value of $38,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired 9,900 shares of company stock worth $69,201 in the last three months.

A number of hedge funds and other institutional investors have recently modified their holdings of IMRX. Citadel Advisors LLC bought a new position in Immuneering in the third quarter worth about $52,403,000. BlackRock Inc. bought a new position in Immuneering in the third quarter worth about $40,472,000. Rock Springs Capital Management LP bought a new position in Immuneering in the third quarter worth about $28,935,000. Perceptive Advisors LLC acquired a new stake in shares of Immuneering in the third quarter valued at approximately $18,082,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Immuneering in the fourth quarter valued at approximately $5,077,000. 46.75% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ IMRX opened at $6.39 on Friday. Immuneering has a 12-month low of $5.98 and a 12-month high of $33.99. The stock has a fifty day moving average price of $7.51 and a 200 day moving average price of $16.29.

Immuneering (NASDAQ:IMRXGet Rating) last posted its quarterly earnings data on Thursday, March 10th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03). The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.60 million. On average, analysts forecast that Immuneering will post -2.01 earnings per share for the current year.

Immuneering Company Profile (Get Rating)

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.

Read More

Analyst Recommendations for Immuneering (NASDAQ:IMRX)

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.